摘要
目的:观察替比夫定阻断5例慢性乙型肝炎病毒感染妊娠妇女母婴HBV垂直传播的疗效和安全性。方法:2007年3月至8月,5例慢性乙型肝炎病毒感染并对婴儿HBV垂直传播有高度危险的妊娠妇女于妊娠28周至分娩后1个月期间服用替比夫定600mg,1次/d。5例妊娠妇女的HBV DNA≥1×107。观察其服药前和分娩前HBV DNA水平、肝功能及不良反应。检测新生儿HBV DNA、HBsAg,观察其发育情况,并发症和进行Apgar评分。结果:5例HBV感染的妊娠妊娠妇女中,4例未检出HBV DNA(<5×102拷贝/ml),1例HBV DNA末降至可检测下限(HBV DNA4.56×103拷贝/ml),5例新生儿发育正常,Apgar评分均为10分,HBV DNA<5×102拷贝/ml,HBsAg呈阴性。结论:替比夫定似对阻断母婴HBV垂直传播有效,且不影响婴儿的正常发育。
Objective：To observe the efficacy and safety of telbivudine for preventing mother-to-infant HBV vertical transmission in five HBV-infected pregnant women. Methods： From March to August 2007, 5 chronic HBV-infected women with a high risk for infecting their newborn infants by vertical transmission entered the study. Their HBV DNA levels were ≥ 1 × 10^7 copies/ml. The women were treated with oral telbivudine 600 mg once daily between 28 weeks after pregnancy and 1 month after labour. The changes in the HBV DNA level, liver function, and adverse reactions were observed in the five women. The neonates＇ HBV DNA and HBsAg levels were measured. The neonates＇ developmental status was observed and Apgar scores were performed. Results： Of the 5 pregnant women, 4 pregnant women＇s HBV DNA levels were not detected （ 〈 5 × 10^2 copies/ml）. One pregnant woman＇s HBV DNA level was 4.56 × 10^3 copies/ml. The five neonates were normally developed, and Apgar score was 10. The neonates＇ HBV DHA levels were 〈5 × 10^2 copies/ml, and their HBsAg tests were negative. Conclusion： Telbivudine seems to be effective in the preventing of mother- to-infant HBV vertical transmission and no influence on infant＇s development.
出处
《药物不良反应杂志》
2008年第1期19-21,共3页
Adverse Drug Reactions Journal
